Cargando…
A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics
Because current mainstream anti-glycolipid GD2 therapeutics for neuroblastoma (NB) have limitations, such as severe adverse effects, improved therapeutics are needed. In this study, we developed a GD2 aptamer (DB99) and constructed a GD2-aptamer-mediated multifunctional nanomedicine (ANM) with effec...
Autores principales: | Zhang, Liyu, Wang, Meng, Zhu, Zeen, Chen, Shengquan, Wu, Haibin, Yang, Ying, Che, Fengyu, Li, Qiao, Li, Hui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515170/ https://www.ncbi.nlm.nih.gov/pubmed/34703655 http://dx.doi.org/10.1016/j.omtn.2021.08.021 |
Ejemplares similares
-
A Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy
por: Zhang, Liyu, et al.
Publicado: (2021) -
Novel Aptamer-Functionalized Nanoparticles Enhances Bone Defect Repair By Improving Stem Cell Recruitment
por: Wang, Meng, et al.
Publicado: (2019) -
Programming assembly of biomimetic exosomes: An emerging theranostic nanomedicine platform
por: Xu, Xiao, et al.
Publicado: (2023) -
Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting
por: Sabbih, Godfred O., et al.
Publicado: (2021) -
Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics
por: Wu, Haibin, et al.
Publicado: (2017)